Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives

摘要: Neuroendocrine tumors (NETs) originate from the neuroendocrine cell system in bronchial and gastrointestinal tract can produce hormones leading to distinct clinical syndromes. Systemic treatment of patients with unresectable NETs aims control symptoms related hormonal overproduction tumor growth. In last decades prognosis has improved as a result increased detection early stage disease introduction somatostatin analogs (SSAs) well several new therapeutic options. SSAs are first-line medical production The development next-generation multireceptor targeted radiolabelled analogs, target-directed therapies (as second-line options) further improve progression-free survival NET patients. To date, however, significant prolongation overall systemic not been convincingly demonstrated. Several options combinations will become available upcoming years, although preliminary results preclinical trials encouraging, large, preferrably randomized studies required provide definitive evidence their effect on symptom control.